In the late 1990s, researchers developed ways to steer the development of these cells, and the possibilities for improving medicine seemed endless. If malfunctioning cells were at the root of a particular disease, could new healthy cells tailored to the job fix what was wrong? Scientists and many members of the public were eager to find out.
Anti-abortion groups, however, a key constituency of President George W. Bush, opposed the research, and in 2001 he limited federal funding to a few existing lines of embryonic stem cells, severely curtailing research.
Some in the state of California wanted to get around Bushs restrictions, and Proposition 71 was born.
"(T)hey had this demon they could attack in the campaign the Bush administration," said David Jensen, author of "California's Great Stem Cell Experiment," who also writes the blog California Stem Cell Report. "They could say, 'This is a great opportunity, and the only way we're going to get it done is to do it here in California.'"
The measure created the California Institute for Regenerative Medicine. The stem cell research agency is unique in the U.S.
"No other state has done this kind of level of funding and focus on this kind of thing, said Jensen. It's a really cutting-edge area of science."
A Few Successes
The pace of innovation has been slower than many hoped. As it turned out, grand discoveries were not around the corner, and to date there is no widespread stem cell treatment approved for the public. To date, CIRM has funded more than 64 trials directly and aided in 31 more. Not all have or will result in treatments.
But despite the lack of a marquee cure like one for Alzheimers or Parkinsons, the agency has seen some notable triumphs.
"Probably one of the most spectacular successes they have certainly so far," said Jensen, "is clinical trials that have saved the lives of what they say are 40 children."
Those children were born with severe combined immunodeficiency (SCID), commonly known as "bubble baby syndrome," a rare, generally fatal condition in which a child is born without a working immune system. An FDA-approved gene therapy that grew out of CIRM-funded research can now cure the disease by taking a patients own blood stem cells and modifying them to correct the SCID mutation. The altered cells generate new, healthy blood cells and repair the immune system.
The FDA has also approved two drugs for rare blood cancers that were developed with CIRM funds.
Sandra Dillon, a graphic designer in San Diego, credits one of the drugs with saving her life. She was diagnosed when she was just 28, in 2006. Her doctors told her they would try to manage her symptoms, but that she was going to get progressively sicker.
"Even just the idea of a cure or getting better wasn't even on the table back then," said Dillon, who is featured in ads for the Yes on 14 campaign.
"I remember just praying and begging into the universe, please, someone just look at my disease, please someone help, who is going to look at this thing.
By 2010, Dillon was extremely ill. She connected with a doctor at UC San Diego who received early-stage funding from CIRM and told her she could take part in clinical trials.
"For the first time, there was this moment of, 'Oh, my gosh! There are researchers doing something. And it could help me and I can get access to it.' It was amazing."
The drug received FDA approval in 2019, and today Dillons cancer has retreated to the point where she can live a normal life.
"I love that I am not tethered to a hospital anymore. I can go out on long backpacking trips and hiking and surfing," she said. "I am a completely different person with this drug. And I have a whole future ahead of me."
The original funding raised by Proposition 71 is running out. Proposition 14 would authorize the sale of a new bond to refill the agency piggy bank. Gov. Gavin Newsom, the UC Board of Regents, and scores of patient advocacy groups also support the measure.
Many newspaper editorial boards, however, oppose the proposition, including the San Francisco Chronicle, Mercury News and Los Angeles Times.
Right now the state still owes about $1 billion toward the debt created by Proposition 71. If Proposition 14 passes, the yearly price tag to pay off the new bond would be about $260 million per year for about 30 years.
One of the selling points of the original proposition was the potential for the state to earn big money in royalties from the treatments it helped develop, says Jeff Sheehy, an HIV patient advocate and the only CIRM board member to oppose Proposition 14.
"The promises were made that this would pay for itself. We would be able to pay back the bonds with the money we would get from royalties, etc., etc.
That has not worked out as envisioned: CIRM estimates it has received less than $500,000 in royalties. Early this year, Forty Seven, a company whose therapies were heavily funded by CIRM, sold to Gilead for $4.9 billion. While millions went to various researchers, neither CIRM nor the state of California received anything.
One of the flaws in the original measure is that we [the agency] cannot hold stock in the products that we develop," says Sheehy. "And that's because the California Constitution says that the state of California cannot, as a government entity, hold equity.
Proposition 14 makes it impossible for the state to use profits from its investment on, say, schools or other funding priorities. Instead, any royalties earned must be fed back into programs to make CIRM-funded treatments more affordable.
"What it does is it basically takes all of our returns that we get from this and gives it back to the pharmaceutical and biotech companies," said Sheehy. "It becomes just a blatant giveaway to these companies when we should be requiring access and requiring fair pricing."
Sheehy says he supports medical research, but doesn't like the state going into more debt to pay for it. The greater the state's obligations in bond money, which has to be paid back with interest, the less there is in the general fund, and Sheehy says the state has more pressing needs than stem cell research things like housing, education and transportation.
"The biggest and perhaps the most compelling reason why I feel so strongly that this is not a good idea is that we simply cannot afford it, he said. "If we think this is so important," asks Sheehy, "why don't we just don't pay for [this research] out of the general fund? It would be cheaper.
Opponents of Proposition 14 also point to longstanding complaints of conflicts of interest among the agency board. Most of the $3 billion distributed by the agency has gone to institutions with connections to board members. Critics say the structural conflicts of interest between the board and agency are not addressed in the new measure. Proposition 14 would balloon an already huge board of 29 members to 35.
Funding needs for stem cell research also are not as acute as they were back in 2004. The federal National Institutes of Health now funds some basic stem cell research, spending about $2 billion a year, with $321 million of that going toward human embryonic stem cell research. And private ventures, like nonprofits started by tech billionaires, are pouring more money into biotech.
The problem with assuming that, says Melissa King, executive director of Americans for Cures, the stem cell advocacy group behind the Yes on 14 campaign, is that CIRM fills a neglected funding need.
The NIH does not fund clinical trials at nearly the rate that CIRM can and has been, King said.
She says that's important because of what she calls the "Valley of Death," where promising early-stage research frequently fails to translate into promising treatments that can be tested in clinical-stage research. (What works well in a test tube often does not work well in an organism.) This weeding-out process is costly but necessary. And its where CIRM focused a lot of its effort.
The first- and maybe even second-phase clinical trials, its very difficult to get those funded, King said. It is too much of a risk for business to take on on its own. Venture [capital] isnt going there. Angel [funding] isnt going there.
What voters have to ask themselves, says writer Jensen, is whether stem cell funding is "a high priority for the state of California? Different people make different judgments about that."
CIRM supporters say if Prop. 14 doesn't pass, critical research will stall. Others say federal and private funding will step in and fill the gap.
Absent new funding, the institute expects it will wind down operations leading to a complete sundown in 2023.
Read the original:
- Accelerating Sales in North America to Drive the Stem Cell Therapy market between 2020 and 2030 - Cheshire Media - December 3rd, 2020
- Human Embryonic Stem Cells Market in Global : Current and the Future Trends: Astellas Pharma Inc/ Ocata Therapeutics, Stemcell Technologies Inc - The... - December 3rd, 2020
- Stem Cells Market Size on Target to Reach US$ 17.79 Billion 2027 - Cheshire Media - December 3rd, 2020
- GFI1: New Role Uncovered for a Protein Involved in Hearing : The Hearing Journal - LWW Journals - December 3rd, 2020
- Human Embryonic Stem Cells (HESC) Market 2019 | Analyzing The Impact Followed By Restraints, Opportunities And Projected Developments | DataIntelo -... - December 1st, 2020
- Stem Cell Manufacturing Market Analysis by Industry Size, Share, Key Drivers, Growth Factors, Demands, Top Manufacturers- Merck Group, Becton,... - December 1st, 2020
- Stem Cells Market is Expected to Thrive at Impressive CAGR by 2025 - The Haitian-Caribbean News Network - December 1st, 2020
- This Date in UCSF History: Election Offers Mixed Bag of Results - Synapse - December 1st, 2020
- Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19) - Cheshire Media - December 1st, 2020
- Stem Cell Assay to Register Substantial Expansion by 2026| Merck, Thermo Fisher Scientific, GE Healthcare - The Haitian-Caribbean News Network - December 1st, 2020
- Autism genes affect development of neurons and glia - Spectrum - November 28th, 2020
- Stem Cell Medical Research to Expand in California Following Passage of Prop. 14 - Times of San Diego - November 28th, 2020
- TRF2-mediated telomere protection is dispensable in pluripotent stem cells - Nature.com - November 26th, 2020
- Stem Cell Therapy Global Market Report 2020-30: Covid 19 Growth and Change - Yahoo Finance UK - November 26th, 2020
- Stem Cells Market 2020: Rising with Immense Development Trends across the Globe by 2027 - The Market Feed - November 26th, 2020
- Stem Cell Characterization and Analysis Tool Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19... - November 26th, 2020
- Global Regenerative Medicine Market 2020-2025: Opportunities with the Implementation of the 21st Century Cures Act - Yahoo Eurosport UK - November 26th, 2020
- Mount Sinai Cardiologist Awarded $2.9 Million NIH Grant to Advance Work with Stem Cells and Heart Repair after Heart Attack - Cath Lab Digest - November 25th, 2020
- Dr. David Steenblock - Stem Cells and Regenerative Medicine - BlogTalkRadio - November 25th, 2020
- Breakthroughs in Stem Cell Based Treatment of Heart Disease - The Connecticut College Voice - November 25th, 2020
- Stem Cell Therapy Market To Observe Exponential Growth By 2020-2027 | Reports Globe - Cheshire Media - November 25th, 2020
- The Stem Cell Characterization and Analysis Tools Market to grow incomparably in the next decade - The Market Feed - November 25th, 2020
- University of Alberta research team poised to cure diabetesagain - Wetaskiwin Times Advertiser - November 23rd, 2020
- New Role For Serotonin Identified In The Evolution Of The Developing Brain - Anti Aging News - November 18th, 2020
- AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update - Business Wire - November 18th, 2020
- Stem Cell Banking Market is Projected to Reach $6,956 million by 2023 | Leading key players are Cord Blood Registry, ViaCord, Cryo-Cell, China Cord... - November 14th, 2020
- California approves billions for stem-cell research - Modern Healthcare - November 14th, 2020
- Cell Freezing Media for Cell Therapy Market 2020 Strategic Assessment BioLife Solutions, Thermo Fisher Scientific, GE Healthcare - KYT24 - November 14th, 2020
- The heart of a mouse embryo was first created from stem cells - FREE NEWS - November 11th, 2020
- Genetic Mechanism Identified in Neonatal Diabetes Could Offer Insights into Other Forms of the Disease - Genetic Engineering & Biotechnology News - November 11th, 2020
- The story of mRNA: From a loose idea to a tool that may help curb Covid - STAT - November 11th, 2020
- Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis - PRnews Leader - November 10th, 2020
- Californias stem cell measure ahead by narrow margin with millions of ballots still left to count - The Mercury News - November 8th, 2020
- Human Embryonic Stem Cells (HESC) Market 2020 Manufacturer Analysis, Emerging Trends, Top Companies and Forecast to 2027 - TechnoWeekly - November 8th, 2020
- Global Stem Cell Therapy Market Growth Factor with Regional Forecast, Segmentation, Investment Opportunities, Industry Research and End User Analysis... - November 8th, 2020
- Voters asked to approve $5.5 billion for stem cell research - Lebanon Express - November 8th, 2020
- U.S. elections bring wins and losses for research community - Science Magazine - November 8th, 2020
- Stem Cell Characterization and Analysis Tool Market : By Component, by Application, by Component Mode, and By Region Global Forecast up to 2026 -... - November 4th, 2020
- Stem Cell Therapy Market To Exceed Revenues Worth US$ By The End Of 2020 2027 - Eurowire - November 4th, 2020
- Stem Cell Manufacturing Market 2020 Global Industry Analysis, Size, Growth, Trends, Share, COVID-19 Impact Analysis, and Forecast 2027| Merck Group,... - November 4th, 2020
- Global Stem Cells Market 2020 Industry Demand, Share, Global Trend, Top Key Players Update, Business Statistics And Research Methodology By Forecast... - November 4th, 2020
- Autologous Stem Cell Based Therapies Market to Witness Increase in Revenues by 2020-2026 - PRnews Leader - November 2nd, 2020
- Study Identifies Pitfall for Correcting Mutations in Human Embryos with CRISPR - Columbia University Irving Medical Center - October 31st, 2020
- Local researchers make stem cell breakthrough - Times of Malta - October 25th, 2020
- Happiness neurotransmitter serotonin plays role in evolutionary expansion of the neocortex - News-Medical.net - October 25th, 2020
- Mice Model Market Research Report 2020 - Global Forecast to 2025 & Cumulative Impact of COVID-19 - ResearchAndMarkets.com - Business Wire - October 22nd, 2020
- For researchers, including some in St. John's, gene editing is now as a precise as film editing - TheChronicleHerald.ca - October 22nd, 2020
- Competitive Landscape of Human Embryonic Stem Cells (HESC) Market 2020 | Global Industry Size, Volume, Trends and Revenue Forecast to 2025 - The Think... - October 20th, 2020
- Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Stock Market Vista - October 20th, 2020
- The Infodemic: Was Regeneron COVID-19 Treatment Developed Using Stem Cells and Fetal Tissue? - Voice of America - October 17th, 2020
- I've Spent Decades Studying How People Build Their Families. Here's What I've Learned Matters Most - TIME - October 14th, 2020
- Was Trump's Regeneron 'Cure' Developed Using Stem Cells and Fetal Tissues? - Snopes.com - October 14th, 2020
- Election 2020: Prop. 14 would boost funding on stem-cell research - San Francisco Business Times - October 10th, 2020
- Factcheck: Regenerons use of embryonic stem cells - Security Boulevard - October 10th, 2020
- Antibody cocktail given to Trump is controversial, and not only because its still under trial - ThePrint - October 10th, 2020
- The global regenerative medicine market is projected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9% - Yahoo... - October 10th, 2020
- University of Wisconsin Researchers Use Stem Cells to Treat Parkinson's - Gilmore Health News - October 10th, 2020
- Thinking It Through: Only two of 12 statewide propositions should be approved - VVdailypress.com - October 10th, 2020
- Mesoblast Needs A Solution To MSC Scalability Issues - Cynata Therapeutics Has An Answer - Seeking Alpha - October 10th, 2020
- Regenerative Medicine Market | Increasing Prevalence of Chronic Diseases to Boost the Market Growth | Technavio - Business Wire - October 10th, 2020
- Stem Cell Characterization and Analysis Tool Market Set to Witness an Uptick during 2020 2026 - The Daily Chronicle - October 5th, 2020
- Stem Cell Therapy Market Growth Factors, Rising Trends and Outlook 2020 to 2027 - X Herald - October 5th, 2020
- Cell Freezing Media for Cell Therapy Market Statistics and Research Analysis Released in Latest Industry Report 2020 | COVID19 Impact Analysis With... - October 5th, 2020
- Stem cell studies probe origins of the placenta - Science - October 2nd, 2020
- No on Prop 14: Not the best way to support stem-cell research - Los Angeles Times - October 2nd, 2020
- Majority of Respondents Support Chimeric Animal Research: Survey - The Scientist - October 2nd, 2020
- $1.9 Billion Mice Model Market by Mice Type, Technology, Application, Service, Care Products - Global Forecast to 2025 - ResearchAndMarkets.com -... - October 2nd, 2020
- Cell Harvesting Market to Witness Steady Expansion During 2018-2023 - The Market Records - October 2nd, 2020
- Global Human Embryonic Stem Cells Market 2020 to Witness Huge Growth by 2026 | Top Key Players; Lonza Group Ltd., Life Technologies Corporation,... - September 28th, 2020
- Stem Cell Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily Chronicle - September 28th, 2020
- Hair loss treatment: Breakthrough research links one ingredient to hair growth - Express - September 28th, 2020
- Cell Freezing Media for Cell Therapy Market To Witness Growth Acceleration Duri - News by aeresearch - September 28th, 2020
- Stem Cell Characterization and Analysis Tool Market Share, Sales Channels and Overview Till 2025 - The Research Process - September 26th, 2020
- Human Embryonic Stem Cells (HESC) Market is Expected to Witness Significant Growth-Says QYResearch | , ESI BIO, Thermo Fisher, BioTime, MilliporeSigma... - September 20th, 2020
- Species-specific pace of development is associated with differences in protein stability - Science Magazine - September 20th, 2020
- The Fascinating Story of Q Stock BioRestorative Therapies Inc (OTCMKTS: BRTXQ) - MicroCap Daily - September 20th, 2020
- Global Stem Cell Therapy Market 2020 Research on Import-Export Details, Business Standards and Forecast to 2025 - Scientect - September 16th, 2020
- Insights Into the Structure and Function of the Immortality Protein - Technology Networks - September 15th, 2020
- Global Cell Freezing Media for Cell Therapy Industry Report 2020 History, Present and Future - Express Journal - September 15th, 2020
- Patenting Stem Cell Inventions in India- What to Expect? - Lexology - September 11th, 2020